KPTI Earnings & Financial Statements
Karyopharm Therapeutics Inc.
$0.32
-$0.11(-26.30%)
31
Overall
40
Value
9
Tech
44
Quality
Market Cap
$7.14M
Volume
2.04M
52W Range
$0.57 - $10.99
Target Price
$8.80
KPTI earnings and financial statements: Karyopharm Therapeutics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
KPTI Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $146.07M | $145.24M | $146.03M | $157.07M | $209.82M |
| Cost of revenue | $5.95M | $6.01M | - | - | $3.40M |
| Operating income | -$90.71M | -$119.44M | -$129.54M | -$142.20M | -$98.27M |
| EBITDA | -$139.31M | -$32.23M | -$117.61M | -$138.49M | -$94.64M |
| Net income | -$196.04M | -$76.42M | -$143.10M | -$165.29M | -$124.09M |
| EPS (diluted) | $-17.93 | $-13.95 | $-18.75 | $-30.30 | $-24.75 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $108.42M | $164.42M | $240.44M | $358.17M | $305.31M |
| Total liabilities | $401.34M | $350.44M | $376.64M | $374.83M | $384.98M |
| Shareholders’ equity | -$292.93M | -$186.02M | -$136.21M | -$16.66M | -$79.67M |
| Cash and equivalents | $60.54M | $62.48M | $52.23M | $135.19M | $190.46M |
| Long-term debt | $100.54M | $101.31M | $173.71M | $176.20M | $178.26M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$75.37M | -$127.49M | -$92.72M | -$149.55M | -$107.12M |
| Capital expenditure | - | -$142.0K | - | -$118.0K | -$5.71M |
| Free cash flow | -$75.37M | -$127.63M | -$92.72M | -$149.55M | -$112.83M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KPTI | $0.32 | -26.3% | 2.04M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Karyopharm Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW